CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 3.21: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
788.08MUSDvs all stocks (USD)
Revenue (TTM)
35.54MUSDvs all stocks (USD)
Profit Margin
-166.40%vs Biotechnology peers
Beta
2.08xvs all stocks
52-Week Change
52.10%vs all stocks
Market Capitalization
788.08MUSDvs all stocks (USD)
Enterprise Value
457.30MUSDvs all stocks (USD)
Forward P/E
-7.55xvs Biotechnology peers
Price to Sales (TTM)
22.45xvs Biotechnology peers
Price to Book (MRQ)
2.49xvs Biotechnology peers
Enterprise to Revenue
12.87xvs Biotechnology peers
Enterprise to EBITDA
-7.54xvs Biotechnology peers
Profit Margin
-166.40%vs Biotechnology peers
Operating Margin
-191.77%vs Biotechnology peers
Return on Assets (TTM)
-16.89%vs Biotechnology peers
Return on Equity (TTM)
-34.28%vs Biotechnology peers
Revenue (TTM)
35.54MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2210USDUpdated Jul 18, 2026Quarterly Revenue Growth
-79.90%vs Biotechnology peers
Gross Profit (TTM)
35.54MUSDvs all stocks (USD)
EBITDA (TTM)
-60.62MUSDvs all stocks (USD)
Net Income (TTM)
-62.14MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-79.85%vs Biotechnology peers
Operating Cash Flow (TTM)
-80.09MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-41.91MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 18, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
76.20MUSDFY2025 · Dec 31, 2025Operating Income
-22.36MUSDvs all stocks (USD)
Pre-tax Income
-17.13MUSDFY2025 · Dec 31, 2025Income Tax Expense
238.00KUSDFY2025 · Dec 31, 2025Net Income
-17.37MUSDFY2025 · Dec 31, 2025EBIT
-22.36MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.99MUSDFY2025 · Dec 31, 2025Research & Development
68.73MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.84MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.21MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-17.37MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-69.49MUSDFY2025 · Dec 31, 2025Free Cash Flow
-69.71MUSDDerived from operating cash flow minus capital expenditure. This filing charges 1.38M of depreciation against 220K of capital expenditure, and its own free-cash-flow line reads -75.81M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
14.19MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-17.37MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
1.38MUSDFY2025 · Dec 31, 2025Stock-based Compensation
6.30MUSDFY2025 · Dec 31, 2025Other Non-cash Items
4.48MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
221.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-65.60MUSDFY2025 · Dec 31, 2025Capital Expenditures
-220.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-192.52MUSDFY2025 · Dec 31, 2025Sale of Investments
133.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-59.74MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
109.64MUSDFY2025 · Dec 31, 2025Shares Outstanding
217.69MSharesUpdated Jul 18, 2026Float Shares
186.26MSharesUpdated Jul 18, 2026Shares Short
35.57MSharesUpdated Jul 18, 2026Short Ratio
6.10daysvs all stocks
Short % of Shares Outstanding
18.54%vs all stocks
% Held by Insiders
0.53%vs all stocks
% Held by Institutions
96.35%vs all stocks
Total Cash (MRQ)
346.71MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.59USDUpdated Jul 18, 2026Total Debt (MRQ)
2.86MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0089xvs Biotechnology peers
Current Ratio (MRQ)
10.38xvs Biotechnology peers
Book Value per Share (MRQ)
1.47USDUpdated Jul 18, 2026Total Assets
151.57MUSDvs all stocks (USD)
Total Current Assets
143.92MUSDFY2025 · Dec 31, 2025Total Liabilities
52.56MUSDFY2025 · Dec 31, 2025Total Non-current Assets
7.64MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.94MUSDFY2025 · Dec 31, 2025Total Current Liabilities
46.62MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
12.67MUSDFY2025 · Dec 31, 2025Other Short-term Investments
124.39MUSDFY2025 · Dec 31, 2025Accounts Receivable
2.01MUSDFY2025 · Dec 31, 2025Accounts Payable
1.30MUSDFY2025 · Dec 31, 2025Short-term Debt
4.24MUSDFY2025 · Dec 31, 2025Deferred Revenue
26.88MUSDFY2025 · Dec 31, 2025Long-term Debt
0.00USDFY2025 · Dec 31, 2025Other Non-current Liabilities
4.35MUSDFY2025 · Dec 31, 2025Common Stock (Book)
2.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-711.95MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
99.01MUSDvs all stocks (USD)
52-Week Low
1.72USDUpdated Jul 18, 202652-Week High
8.21USDUpdated Jul 18, 202652-Week Change
52.10%vs all stocks
Beta
2.08xvs all stocks
50-Day MA
3.53USDUpdated Jul 18, 2026200-Day MA
4.18USDUpdated Jul 18, 2026Avg 10-Day Volume
3.39MSharesUpdated Jul 18, 2026Avg 30-Day Volume
5.04MSharesUpdated Jul 18, 2026Diluted EPS (TTM)
-0.5200USDUpdated Jul 18, 2026Other Income / Expense
28.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
Where is this company structurally exposed?
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 22.45Revenue Growth YoY: -0.80
Financial Health
Altman Z-Score 3.21: safe zoneNotable
Altman Z-Score: 3.21
High structural barrier to entryNotable
Barrier to Entry: 1.36
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Jiangsu Jibeier Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Design Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Bio-Sincerity Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Genomma Lab Internacional S.A.B. de C.V.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jacobio Pharmaceuticals Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Chongqing Lummy Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shanxi Zhendong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guizhou Sanli Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Tong Ren Tang Technologies Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Aarti Pharmalabs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Phoenix Asia Holdings Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital ElevatedPartial Recovery After Sharp Decline
Samyang NC Chem Corporation
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital ElevatedPartial Recovery After Sharp Decline
Hantech Ltd.
3 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityIndustry-Benchmarked Return on Capital ElevatedPartial Recovery After Sharp Decline